Astral Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 1.71 M
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -62.78%
- Profit Growth -119.34%
- Ebitda -21.10%
- Net Worth -0.04%
- Total Assets -24.48%
About Astral Pharmaceuticals
Astral Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 May 2006 and has a history of 18 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Anovaa Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.71 M, as per Ministry of Corporate Affairs (MCA) records.
Ajaay Jajodia and Shyam Jajodia serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24231MH2006PTC161708
-
Company No.
161708
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 May 2006
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Astral Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajaay Jajodia
|
Director | 15-Apr-2022 | Current |
|
Shyam Jajodia
|
Director | 04-Jul-2008 | Current |
Financial Performance of Astral Pharmaceuticals.
Astral Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 62.78% decrease. The company also saw a substantial fall in profitability, with a 119.34% decrease in profit. The company's net worth dipped by a decrease of 0.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Astral Pharmaceuticals?
In 2023, Astral Pharmaceuticals had a promoter holding of 8.75% and a public holding of 91.25%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Win Chemicals LimitedAjaay Jajodia and Shyam Jajodia are mutual person
-
Alzeeno Merchants LlpShyam Jajodia is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Astral Pharmaceuticals?
Unlock and access historical data on people associated with Astral Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Astral Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astral Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
